Eversept Partners, LP Celyad Oncology Sa Transaction History

Eversept Partners, LP

  • $1.26 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 13, 2019
SELL
$16.0 - $28.17 $26,816 - $47,212
-1,676 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$26.49 - $31.86 $295,734 - $355,685
-11,164 Reduced 86.95%
1,676 $44,000
Q2 2018

Nov 08, 2023
BUY
$26.05 - $35.15 $334,482 - $451,326
12,840 New
12,840 $381,000
Q2 2018

Aug 14, 2018
BUY
$26.05 - $35.15 $334,482 - $451,326
12,840 New
12,840 $382,000

About Celyad Oncology SA

CYAD Quotes by TradingView
  • Ticker CYAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,594,000
  • Market Cap $11.7M
  • Description
  • Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cance...
More about CYAD
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email